Meta agreed to settle a major lawsuit on Thursday with a school district in Kentucky over claims that its social networks are designed to be addictive, leading to harm in children. The settlement comes less than three weeks before the case was scheduled to go to trial in federal court in California. About 1,200 school districts from across the US came together to each sue Meta, TikTok, Snap and YouTube for allegedly fueling a mental health crisis in children. TikTok, Snap and YouTube settled their suits with Kentucky over the past couple of weeks. “We’ve resolved this case amicably and remain focused on our longstanding work to build protections like Teen Accounts that help teens stay safe online, while giving parents simple controls to support their families,” said a Meta spokesperson. The company, which owns Facebook and Instagram, did not disclose the terms of the settlement. A YouTube spokesperson also said the matter was resolved amicably and confidentially and that “for more than a decade, we’ve built YouTube responsibly – working with teachers, administrators, and parents’ groups to give students safer, more helpful experiences online”. TikTok and Snap did not immediately return requests for comment. Breathitt county schools, a small rural district in Kentucky, had ⁠accused the social media companies of designing addictive products that led to students having anxiety and depression and engaging in self-harm. The school district said it was left dealing with the fallout. The lawsuit ​sought more than $60m to cover the costs of mental health needs for students in the district and to pay for a 15-year program to improve the issue. Lawyers ⁠also ​sought a court order requiring the ​social media companies to change the way their platforms worked to have fewer addictive features. Meta’s legal woes are far from over. Attorneys for the school districts said in a statement on Thursday that “our focus remains on pursuing justice for the remaining 1,200 school districts...

1933bkk/iStock via Getty Images Before the market opened on May 21, the management team at Advanced Drainage Systems ( WMS ) announced financial results covering the final quarter of the company's 2026 fiscal year. Even though revenue and adjusted earnings per share came in higher than what analysts anticipated, the stock price was virtually flat. Unfortunately, even though the company continues to expand nicely, the market has been beating up on it quite a bit lately. In February, as an example, I reaffirmed the company as a "Hold" candidate. I acknowledged that the firm was doing great. However, based on its valuation, I didn't see there being market-beating potential. That's why I took a more neutral stance on it. But since then, shares are now down 23.5%, while the S&P 500 is up 6.5%. This is disappointing, though the benefit of it is that the stock is definitely getting closer to being attractively priced. I wouldn't go so far as to say that upgrading it makes sense here. But we are nearing the point where that could become feasible. Continued growth goes unrewarded Author - SEC EDGAR Data For the most part, the final quarter of the 2026 fiscal year was a good time for shareholders of Advanced Drainage Systems. Revenue came in at $676.8 million. In addition to being 9.9% above the $615.8 million that the business reported a year earlier, it was also $24.3 million higher than what analysts had hoped to see . This rise in sales was driven by both of the company's operating segments. On that front, a little bit of discussion is needed. In the past, the company had four different operating segments. But now, it has consolidated operations into two different segments. The largest of these is the Stormwater segment, which includes the Pipe and International segments of the company, as well as its Allied Products & Other operation. Meanwhile, the former Infiltrator segment has become the Wastewater segment. Author - SEC EDGAR Data Revenue for the Stormwater segment to...

油价连续第三天下跌，投资者研判美国和伊朗是否接近达成和平协议，从而令霍尔木兹海峡航运活动重启。 WTI下跌1.9%，结算价每桶96.35美元，创下近两周来的最低水平。 7月布伦特下跌2.3%，结算价报每桶102.58美元。 美伊双方在周四均发出信号，暗示在实现永久停火及重新开放海峡方面取得进展。 结算后交易时段，原油收复部分失地，因伊朗总统表示，该国在谈判中“不会退让”。 近几日来，原油期货市场对围绕和平谈判进展的各类新闻头条高度敏感，交易员们唯恐突然达成协议导致自己措手不及。 “虽然谈判时间变长，且原油库存日趋紧张，但在局势没有升级的情况下，停火状态维持得越久，市场就越倾向于相信最终将迎来外交解决方案，”加拿大帝国商业银行私人财富管理集团的高级能源交易员Rebecca Babin表示。 尽管周四市场基调偏空，但当前油价仍较战争爆发前高出近40%。 机构研究的一项调查显示，绝大多数市场参与者预计，受战争引发的结构性变化影响，原油期货价格在未来数年内将持续包含一定的风险溢价。 这种潜在的结构性变化之一是：伊朗正与阿曼商讨建立一套永久性的通行费征收机制，旨在通过制度化的方式进一步加强对海峡航运的管控。 责任编辑：何云

Qualcomm (NASDAQ:QCOM) Trading 5.4% Higher - Still a Buy? MarketBeat

NVIDIA (NASDAQ:NVDA) Trading Down 1.8% - What's Next? MarketBeat

Taiwan Semiconductor Manufacturing (NYSE:TSM) Stock Price Up 1.5% - Time to Buy? MarketBeat

Micron Technology (NASDAQ:MU) Trading 4.1% Higher - What's Next? MarketBeat

IMAX Corp．股价盘后跃升12%，此前媒体报道称，该公司正在研究出售事宜，并已接洽一些娱乐公司作为潜在买家。 报道援引知情人士称，出售进程目前仍处于早期阶段，最终也有可能无法达成交易 截至周四收盘，IMAX股价今年累计下跌8.3%。 责任编辑：何云

gorodenkoff/iStock via Getty Images Shares of Crispr Therapeutics AG ( CRSP ), the Zug, Switzerland-based biotechnology company, have been stuck within a trading range for about four and a half years now. Investor enthusiasm around the Casgevy launch – a one-time CRISPR/Cas-9 technology-based curative treatment for Sickle Cell Disease (SCD), specifically those with frequent vaso-occlusive crises (VOC), and Transfusion Dependent Beta Thalassemia (TDT) – has now muted, due to its slow commercial roll-out, the drawn-out revenue recognition process, and the lower-than-expected patient uptake. Seeking Alpha The treatment, developed with Vertex ( VRTX ), which has the lion’s share of a 60/40 profit/costings split (60% for Vertex/40% for Crispr), has a very high success rate (>98% efficacy) according to the most recent long-term data , but takes 9-12 months to reach completion, with revenue only recognized at the end of the process. Moreover, due to the patient needing to undergo myeloablative therapy (chemotherapy) beforehand as part of the preconditioning protocol – to remove old stem cells so they can be replaced with new, Casgevy-treated stem cells – it is hardly a “home run,” as it could cause organ damage and in almost all cases also leads to male infertility. Many patients, it would seem, would rather have children naturally or simply can’t afford or don’t have access to fertility treatments, which makes the decision of whether to undertake this curative treatment a very difficult one. It’s not a simple choice, which then leads us to ask some important questions about the investment case for Crispr: How should we now view the TAM for this treatment? Should it be reduced as we factor in the moderate percentage of people that will shun it? How should we view the competitive landscape for the in vivo treatment for SCD/TDT that Crispr and Vertex are working towards that would not require myeloablative preconditioning, as well as the work to find gentler preconditioning ...

Qualcomm Inc stock (US7475251036): AI chip momentum meets regulatory and earnings pressures AD HOC NEWS

Key Points B Group bought 750,000 shares in ADMA Biologics during the first quarter. The quarter-end position value declined by $15.93 million, reflecting both share purchases and stock price movements. The transaction represented a roughly 9% change in the fund’s 13F assets under management. The quarter-end stake stood at 3,207,542 shares valued at $28.90 million. 10 stocks we like better than Adma Biologics › B Group disclosed a purchase of 750,000 shares of ADMA Biologics (NASDAQ:ADMA) in a May 15, 2026, SEC filing, an estimated $11.84 million trade based on quarterly average pricing. What happened According to a May 15, 2026, SEC filing, B Group, Inc. increased its position in ADMA Biologics by 750,000 shares, with the estimated transaction value at $11.84 million based on the quarterly average price. The fund’s holding at quarter’s end stood at 3,207,542 shares, worth $28.90 million. The net position change, including share additions and price fluctuations, was a decrease of $15.93 million over the quarter. What else to know B Group, Inc. added to its ADMA Biologics holding, which made up 21.43% of its 13F assets under management after the trade Top holdings after the filing: NASDAQ: ADMA: $28.90 million (21.4% of AUM) NASDAQ:PALI: $19.97 million (14.8% of AUM) NASDAQ:PRAX: $10.71 million (7.9% of AUM) NASDAQ:CLLS: $10.40 million (7.7% of AUM) NASDAQ:ZLAB: $8.48 million (6.3% of AUM) As of Thursday, ADMA Biologics shares were priced at $8.46, down about 58% over the past year and well underperforming the S&P 500, which is instead up about 27% in the same period. Company Overview Metric Value Market Capitalization $2 billion Revenue (TTM) $509.9 million Net Income (TTM) $165.35 million Price (as of Thursday) $8.46 Company Snapshot ADMA develops, manufactures, and markets specialty plasma-derived biologics, including BIVIGAM, ASCENIV, and Nabi-HB, primarily for the treatment of immune deficiencies and infectious diseases. The firm operates a vertically integrated...

While there are some shocking revelations in SpaceX’s S-1 as it gets ready to become a public company, Elon Musk’s total control of the company perhaps isn’t one of them. I could argue that the oddball provision where Elon Musk gets up to a billion more shares to add to his already oversized, company-controlling cache once a million people are living on Mars (yes, really), is perhaps the most jaw-dropping. It is also fairly unserious. Musk controls and can vote those shares now, by the way. But even a billion extra super-voting rights shares are immaterial in this company’s setup because Musk is, by miles, the largest shareholder in the company. He owns just under 850 million Class A shares, entitled to 1 vote per share, and another nearly 5.6 billion Class B shares, entitled to 10 votes per share. That includes the billion shares contingent on a million people living in a SpaceX company-town colony on Mars. Sci-fi conditions aside, there are a handful of people who stand to benefit most should the SpaceX IPO be a success and the stock continue to do well in the future: the 5% shareholders. These are the people who hold at least 5% of the company. While the company has not yet said how many shares it will sell or at what price, the whisper number on the street is that this IPO will raise a whopping $75 billion, with a post-money valuation of $1.7 trillion. At those numbers, even a 1% stake is worth $17 billion. Here’s the rundown of who owns what. Elon Musk, founder, CEO, CTO and chairman. Total SpaceX stock holdings: just over 6.42 billion shares. Antonio Gracias, investor and board member. Total SpaceX stock holdings: just over 503.4 million shares Gracias is founder and CEO and of Valor Management and a long-time Musk friend, pro-Musk board member and financier. He was on Tesla’s board from its startup days through the years after its IPO. He was also a board member of Musk’s solar company Solar City during its controversial sale to Tesla. He’s backed and held bo...

格隆汇5月22日｜据伊朗学生通讯社：（美伊）信息交流旨在达成协议框架。

格隆汇5月22日｜据伊朗学生通讯社：伊朗与美国之间的消息交流正在进行，巴基斯坦方面从中进行调解。

Image source: The Motley Fool. Thursday, May 21, 2026 at 4:15 p.m. ET Call participants Chief Executive Officer — James G. Conroy Group President and Chief Operating Officer — Michael J. Hartshorn Executive Vice President and Chief Financial Officer — William Sheehan Senior Vice President, Investor Relations — Connie Kao Need a quote from a Motley Fool analyst? Email [email protected] Takeaways Total sales -- $6 billion, reflecting 21% growth driven by a 17% increase in comparable store sales. -- $6 billion, reflecting 21% growth driven by a 17% increase in comparable store sales. Comparable store sales -- Up 17%, attributed primarily to growth in transaction volume and a double-digit increase in customer count across income levels, ethnicities, and age groups. -- Up 17%, attributed primarily to growth in transaction volume and a double-digit increase in customer count across income levels, ethnicities, and age groups. Operating margin -- Expanded to 13.4%, representing a 120 basis point increase from the prior-year period. -- Expanded to 13.4%, representing a 120 basis point increase from the prior-year period. Net income -- $650 million, up from $479 million in the same quarter last year. -- $650 million, up from $479 million in the same quarter last year. Earnings per share (EPS) -- Rose 37% to $2.02 compared to $1.47. -- Rose 37% to $2.02 compared to $1.47. Inventory -- Consolidated inventories increased 12%, with packaway inventory at 36% of the total, down from 41% in the prior year. -- Consolidated inventories increased 12%, with packaway inventory at 36% of the total, down from 41% in the prior year. Buybacks -- Repurchased 1.5 million shares for $319 million under a new two-year $2.55 billion authorization, maintaining a target to buy back $1.275 billion of stock in 2026. -- Repurchased 1.5 million shares for $319 million under a new two-year $2.55 billion authorization, maintaining a target to buy back $1.275 billion of stock in 2026. Store openings -- Ope...

Monica Schipper IMAX ( IMAX ) is exploring a sale and has approached entertainment firms as possible bidders. The process is in its early stage and may not result in any transaction, according to a WSJ report on Thursday, which cited people familiar with the matter. IMAX shares have risen 26% over the past year, though they have dropped 8.3% year-to-date. IMAX has a market cap of $1.9 billion. More on IMAX IMAX Corporation (IMAX) Presents at J.P. Morgan 54th Annual Global Technology, Media and Communications Conference Transcript IMAX Corporation 2026 Q1 - Results - Earnings Call Presentation IMAX Corporation (IMAX) Q1 2026 Earnings Call Transcript ‘Michael’ moonwalks back to No. 1 as domestic box office hits $106M weekend IMAX is defended by analysts after a post-earnings stumble

Infleqtion (NYSE:INFQ) , a developer of quantum computing and sensing solutions using neutral-atom technology, closed at $14.70, up 31.44% for the session. The stock jumped after it signed a Letter of Intent with the U.S. Department of Commerce’s CHIPS R&D department for $100 million in potential funding. Investors are watching how prospective government backing could drive future contract wins. Trading volume reached 74.8 million shares, about 889% above its three-month average of 7.6 million shares. Infleqtion IPO'd in 2026 and has fallen 6% since going public. The S&P 500 added 0.18% to finish at 7,446, while the Nasdaq Composite inched up 0.09% to close at 26,293. Among other quantum-computing names, IonQ closed at $58.90 (+12.25%), and Rigetti Computing finished at $22.04 (+30.57%), underscoring intense interest in quantum-computing plays. Today’s news is very interesting for investors interested in quantum computing -- particularly those holding or considering Infleqtion shares. The company states it already works with “DARPA, the U.S. Department of Energy, NASA, and the U.S. Department of Defense,” so today’s development could deepen these ties. Continue reading

格隆汇5月22日｜消息人士称，美国国土安全部部长马林警告航空公司高管，特朗普政府可能暂停部分“庇护城市”机场的国际旅行处理服务。

财联社5月22日讯（编辑 赵昊） 周四（5月21日），受国际油价持续下滑影响，美股三大指数连两日收升，其中道指刷新历史新高。 截至收盘，道琼斯指数涨0.55%，报50285.66点，升破了5月14日的收盘纪录；标普500指数涨0.17%，报7445.72点；纳斯达克综合指数涨0.09%，报26293.1点。 日内，WTI原油期货7月合约结算价跌1.94%，布伦特原油期货7月合约跌2.32%。美股盘中，一名巴基斯坦参议员表示，美伊谈判正朝着正确的方向发展，并对此持乐观态度。 The Wealth Alliance 首席执行官Robert Conzo表示，“如果油价持续维持在每桶100美元或以上，短期内可能会出现对于通胀上升的担忧，媒体也会大肆渲染风险。” 但Conzo也同时指出，标普500波动率指数（VIX）目前在17左右，表明当下在人工智能普及、盈利增长强劲以及低失业率的环境下，投资者“感觉比较安心”。 英伟达前一日盘后公布的季度业绩报告显示，公司盈利和指引均轻松超出华尔街预期，但股价仍跌1.77%。Conzo评论道，外界“想要的太多了”，这些期望已经变得不切实际。 热门股表现 科技巨头涨跌不一，苹果涨0.91%续收新高，市值达4.479万亿美元。（按市值排列）谷歌C跌0.37%，微软跌0.47%，亚马逊涨1.3%，博通跌0.76%，特斯拉涨0.14%，Meta涨0.38%。 沃尔玛跌7.27%，创2023年以来最大单日跌幅，受累于偏高的燃料成本。IBM涨12.43%，消息称美国将向IBM在内的9家量子计算公司划拨20亿美元。 多只量子计算概念股涨幅达两位数。D-Wave Quantum涨33.37%，Infleqtion涨31.48%，Rigetti Computing涨30.57%，Arqit Quantum涨25.67%。 费城半导体指数涨1.28%，连涨第三天。30只成分股中，20家上涨10家下跌。Arm Holdings涨16.16%，格芯涨14.92%，高通涨5.38%。 光通信概念整体走高，Lumentum涨11.11%，Applied Optoelectronics涨6.99%，Credo Technology涨5.69%，Coherent涨5.44%。 存储概念集体走强，闪迪涨10.75%，希捷科技涨7.91%，Rambus涨6.18%，西部数据涨...

Copart, Inc. (CPRT) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.42 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +4.88%. A quarter ago, it was expected that this company would post earnings of $0.4 per share when it actually produced earnings of $0.36, delivering a surprise of -10%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Copart, which belongs to the Zacks Auction and Valuation Services industry, posted revenues of $1.24 billion for the quarter ended April 2026, surpassing the Zacks Consensus Estimate by 2.39%. This compares to year-ago revenues of $1.21 billion. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Copart shares have lost about 15.6% since the beginning of the year versus the S&P 500's gain of 8.6%. What's Next for Copart? While Copart has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings ...

Zoom Communications (ZM) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $1.41 per share. This compares to earnings of $1.43 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +9.59%. A quarter ago, it was expected that this video-conferencing company would post earnings of $1.48 per share when it actually produced earnings of $1.44, delivering a surprise of -2.7%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Zoom, which belongs to the Zacks Internet - Software industry, posted revenues of $1.24 billion for the quarter ended April 2026, surpassing the Zacks Consensus Estimate by 1.26%. This compares to year-ago revenues of $1.17 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Zoom shares have added about 15.2% since the beginning of the year versus the S&P 500's gain of 8.6%. What's Next for Zoom? While Zoom has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this ea...

Webull Corporation (BULL) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company would post earnings of $0.05 per share when it actually produced earnings of $0.03, delivering a surprise of -40%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Webull Corporation, which belongs to the Zacks Financial - Miscellaneous Services industry, posted revenues of $159.93 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 0.1%. This compares to year-ago revenues of $117.37 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Webull Corporation shares have lost about 10% since the beginning of the year versus the S&P 500's gain of 8.6%. What's Next for Webull Corporation? While Webull Corporation has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power o...